ERAS

About ERAS

Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. The Company’s lead product candidates are ERAS-007 and ERAS-601, which together comprise its first MAPKlamp. ERAS-007 is designed to be an oral inhibitor of ERK1/2, which has been evaluated as a single agent in a Phase I clinical trial in patients with advanced solid tumors completed by Asana. ERAS-601 is an oral SHP2 inhibitor, which is under first-in-human Phase I clinical trial, FLAGSHP-1. The Company’s SHP2 inhibitor is designed to block oncogenic signal transduction and delay the onset of therapeutic resistance, which has the potential to serve as a backbone of combination therapy against RAS/MAPK pathway altered cancers.

Buy US stocks in Australia with $0 brokerage and trade ERAS today!